Short answer
Abbott Laboratories (ABT) filed its Q1 2026 10-Q quarterly report on Apr 29, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $11.2B (up 7.8% year over year) with net income of $1.1B.
Q1 2026 key financials · XBRL
- Revenue
- $11.2B
- +7.8% YoY
- Net income
- $1.1B
- −18.7% YoY
- Operating margin
- 12.0%
- EPS (diluted)
- $0.61
- −19.7% YoY
Source: XBRL data from the Abbott Laboratories (ABT) Q1 2026 10-Q on SEC EDGAR. USD.
Abbott Laboratories Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $11.164B, up 7.8% YoY from $10.358B
- Gross margin 52.4% vs 52.8% YoY
- Best segment Medical Devices $5.539B, up 13.2%; worst Nutritional Products $2.017B, down 6.0%
- Cash $6.8B vs $8.5B; operating cash flow $1.3B, down $102M YoY
- Exact Sciences acquisition $20.6B, funded with $20B debt; remaining assumed debt expected repaid in 2026
- Headwinds: weaker respiratory-test demand, lower nutrition volumes, China diagnostic conditions, healthcare regulatory uncertainty
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Abbott Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.